Hailshadow Additional phase 2 data from a dose escalation cohort of BridgeBio Pharma's ( NASDAQ: BBIO ) achondroplasia candidate infigratinib showed the drug continued to improve height at months 12 and 18. The mean increase in annualized height velocity was +2.51cm/year at 12 months and +2.
50 cm/yr at 18 months compared to baseline. There was also a statistically significant improvement in body proportionality from 2.02 at baseline to 1.
88 at month 18. Investors, however, do not appear to be impressed with the results . In late Monday morning trading, BridgeBio is down ~6.
5% . Achondroplasia is the most common type of dwarfism. BridgeBio ( BBIO ) added that PROPEL 3, its phase 3 trial for infigratinib, is on schedule with enrollment completion planned by the end of the year.
More on BridgeBio Pharma BridgeBio Pharma: Upping An Existing Position (Rating Upgrade) BridgeBio Pharma: Assessing Acoramidis' Market Opportunity, Further Upside Potential Evident BridgeBio reports additional positive data for acoramidis in ATTR-CM Cantor picks 14 undervalued biotech stocks worth a second look Seeking Alpha’s Quant Rating on BridgeBio Pharma.
